Get started
ESPERION THERAPEUTESPERION THERAPEUTESPERION THERAPEUT

ESPERION THERAPEUT

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Forecast Seasonals Bonds

0ET chart


Full chart

0ET upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪419.98 M‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.526 CHF
Net income (FY)
‪−176.17 M‬ CHF
Revenue (FY)
‪97.95 M‬ CHF
Shares float
‪195.06 M‬
Beta (1Y)
3.01

Employees


Employees (FY)
240
Change (1Y)
+41 +20.60%
Revenue / Employee (1Y)
‪484.73 K‬ CHF
Net income / Employee (1Y)
‪−871.87 K‬ CHF

About Esperion Therapeutics, Inc.


Sector
Health Technology
CEO
Sheldon L. Koenig
Headquarters
Ann Arbor
Website
esperion.com
Founded
1998
FIGI
BBG00LVD9YR7
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

0ET news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

0ET highest yielding bonds


PFE5307022
Esperion Therapeutics, Inc. 4.0% 15-NOV-2025
Yield to maturity
8.08%
Maturity date
Nov 15, 2025

Explore more bonds 

Frequently Asked Questions


The current price of 0ET is 2.110 CHF — it has increased by 14.55% in the past 24 hours. Watch ESPERION THERAPEUT stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange ESPERION THERAPEUT stocks are traded under the ticker 0ET.
0ET stock has risen by 14.43% compared to the previous week, the month change is a 47.97% rise, over the last year ESPERION THERAPEUT has showed a −56.05% decrease.
We've gathered analysts' opinions on ESPERION THERAPEUT future price: according to them, 0ET price has a max estimate of 13.96 CHF and a min estimate of 1.79 CHF. Watch 0ET chart and read a more detailed ESPERION THERAPEUT stock forecast: see what analysts think of ESPERION THERAPEUT and suggest that you do with its stocks.
0ET reached its all-time high on Aug 10, 2021 with the price of 13.060 CHF, and its all-time low was 1.426 CHF and was reached on Aug 28, 2024. View more price dynamics on 0ET chart.
See other stocks reaching their highest and lowest prices.
0ET stock is 12.70% volatile and has beta coefficient of 3.01. Track ESPERION THERAPEUT stock price on the chart and check out the list of the most volatile stocks — is ESPERION THERAPEUT there?
Today ESPERION THERAPEUT has the market capitalization of ‪419.98 M‬, it has increased by 10.58% over the last week.
Yes, you can track ESPERION THERAPEUT financials in yearly and quarterly reports right on TradingView.
ESPERION THERAPEUT is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
0ET earnings for the last quarter are −0.13 CHF per share, whereas the estimation was −0.15 CHF resulting in a 14.42% surprise. The estimated earnings for the next quarter are −0.12 CHF per share. See more details about ESPERION THERAPEUT earnings.
ESPERION THERAPEUT revenue for the last quarter amounts to ‪43.75 M‬ CHF, despite the estimated figure of ‪43.48 M‬ CHF. In the next quarter, revenue is expected to reach ‪53.89 M‬ CHF.
0ET net income for the last quarter is ‪−25.02 M‬ CHF, while the quarter before that showed ‪−55.67 M‬ CHF of net income which accounts for 55.06% change. Track more ESPERION THERAPEUT financial stats to get the full picture.
No, 0ET doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 240.00 employees. See our rating of the largest employees — is ESPERION THERAPEUT on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ESPERION THERAPEUT EBITDA is ‪25.08 M‬ CHF, and current EBITDA margin is −133.58%. See more stats in ESPERION THERAPEUT financial statements.
Like other stocks, 0ET shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ESPERION THERAPEUT stock right from TradingView charts — choose your broker and connect to your account.